Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 21 points (0.1%) at 16,093 as of Tuesday, Nov. 26, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,560 issues advancing vs. 1,331 declining with 131 unchanged. The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.1%, and GlaxoSmithKline ( GSK), down 0.9%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Alnylam Pharmaceuticals ( ALNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Alnylam Pharmaceuticals is up $1.76 (2.9%) to $61.73 on light volume. Thus far, 272,419 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 762,500 shares. The stock has ranged in price between $59.84-$61.88 after having opened the day at $60.00 as compared to the previous trading day's close of $59.97. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Alnylam Pharmaceuticals has a market cap of $3.7 billion and is part of the health care sector. Shares are up 219.6% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Alnylam Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Alnylam Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.